Alexion pharmaceuticals stock comprar ou vender

10/01/2020 · Real time Alexion Pharmaceuticals (ALXN) stock price quote, stock graph, news & analysis.

19 Wall Street analysts have issued 1 year price objectives for Alexion Pharmaceuticals' stock. Their forecasts range from $125.00 to $186.00. On average, they anticipate Alexion Pharmaceuticals' share price to reach $154.56 in the next twelve months. This suggests a possible upside of 41.2% from the stock's current price. Comparing the results to its competitors, Alexion Pharmaceuticals Inc reported Total Revenue increase in the 3 quarter 2019 by 23.05 % year on year, while most of its competitors have experienced contraction in revenues by -11.78 %, recorded in the same quarter. ALXN: Alexion Pharmaceuticals, Inc. - Price and Consensus Chart. Get the latest Price and Consensus Chart for Alexion Pharmaceuticals, Inc. from Zacks Investment Research Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). The company is also involved in immune system research related to autoimmune diseases. Alexion Pharmaceuticals could see as much as 30% upside if its rare blood disease drug outperforms its already approved medication, Soliris, in a pair of Phase 3 trials, an analyst said Friday, prodding the company's stock to pop.

In addition, Alexion Pharmaceuticals, Inc. has a VGM Score of B (this is a weighted average of the individual Style Scores which allow you to focus on the stocks 

Stock analysis for Alexion Pharmaceuticals Inc (ALXN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Skip To Content. Skip to content. Bloomberg the Company & Its Products Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Terminal Demo Request. Alexion Pharmaceuticals Inc. advanced stock charts by MarketWatch. View ALXN historial stock data and compare to other stocks and exchanges. Alexion Pharmaceuticals has a market cap of $23.86 B, which represents its current share price of $107.84 multiplied by its outstanding share number of 221.29. As a large-cap company, ALXN's shareholders are exposed to the least amount of risk. 06/02/2019 · Find the latest Alexion Pharmaceuticals, Inc. (ALXN) stock quote, history, news and other vital information to help you with your stock trading and investing. 10/01/2020 · Real time Alexion Pharmaceuticals (ALXN) stock price quote, stock graph, news & analysis. View a list of stocks similar to Alexion Pharmaceuticals Inc. (ALXN) based on sector, industry, asset class and other criteria.

23/11/2019 · Alexion Pharmaceuticals (ALXN) Alexion Pharmaceuticals (ALXN) Stock Soars on Q3 Beat, Outlook. Alexion Pharmaceuticals the team also finds weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on …

ALXN: Alexion Pharmaceuticals, Inc. - Price and Consensus Chart. Get the latest Price and Consensus Chart for Alexion Pharmaceuticals, Inc. from Zacks Investment Research Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). The company is also involved in immune system research related to autoimmune diseases. Alexion Pharmaceuticals could see as much as 30% upside if its rare blood disease drug outperforms its already approved medication, Soliris, in a pair of Phase 3 trials, an analyst said Friday, prodding the company's stock to pop.

23/11/2019 · Alexion is coming off a brutal month where the stock has fallen nearly 30% including a 17% drop over the last four days. This brings the stock down a whopping 50% from its all time high in 2015 and back to 2013 levels when earnings were about half what they are today.

23/11/2019 · Alexion is coming off a brutal month where the stock has fallen nearly 30% including a 17% drop over the last four days. This brings the stock down a whopping 50% from its all time high in 2015 and back to 2013 levels when earnings were about half what they are today.

ALXN - Alexion Pharmaceuticals Inc. Advanced Chart, Quote and financial news from the leading provider and award-winning BigCharts.com.

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with severe and life-threatening rare diseases. Real-time trade and investing ideas on Alexion Pharmaceuticals, Inc. ALXN from the largest community of traders and investors. ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. 19 Wall Street analysts have issued 1 year price objectives for Alexion Pharmaceuticals' stock. Their forecasts range from $125.00 to $186.00. On average, they anticipate Alexion Pharmaceuticals' share price to reach $154.56 in the next twelve months. This suggests a possible upside of 41.2% from the stock's current price. Comparing the results to its competitors, Alexion Pharmaceuticals Inc reported Total Revenue increase in the 3 quarter 2019 by 23.05 % year on year, while most of its competitors have experienced contraction in revenues by -11.78 %, recorded in the same quarter. ALXN: Alexion Pharmaceuticals, Inc. - Price and Consensus Chart. Get the latest Price and Consensus Chart for Alexion Pharmaceuticals, Inc. from Zacks Investment Research Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). The company is also involved in immune system research related to autoimmune diseases. Alexion Pharmaceuticals could see as much as 30% upside if its rare blood disease drug outperforms its already approved medication, Soliris, in a pair of Phase 3 trials, an analyst said Friday, prodding the company's stock to pop.

Get Alexion Pharmaceuticals Inc (ALXN:NASDAQ) real-time stock quotes, news and financial information from CNBC.